ReviewGene therapy2004
Osteoarthritis gene therapy.
Review in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 144 citations in OpenAlex.
- Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2011Trial
- Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.Human gene therapy · 2009Trial
- Co-delivery of IL-1Ra and SOX9 via AAV inhibits inflammation and promotes cartilage repair in surgically induced osteoarthritis animal models.Gene therapy · 2025Article
- The role of FoxO3a in the pathogenesis of osteoarthritis and its therapeutic applications.Frontiers in immunology · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Biomaterial-Based Gene Delivery: Advanced Tools for Enhanced Cartilage Regeneration.Drug design, development and therapy · 2023Review
- Polymeric Nanoparticles for Drug Delivery in Osteoarthritis.Pharmaceutics · 2022Review
- Impact of the bidirectional relationship between communication and cognitive efficacy on orthopedic patient adherence behavior.BMC health services research · 2022Article
- Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation.Frontiers in bioengineering and biotechnology · 2022Review
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.International journal of molecular sciences · 2021Review
- Review
- Where is human-based cellular pharmaceutical R&D taking us in cartilage regeneration?3 Biotech · 2020Review
- Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis.PLoS biology · 2019Article
- The Role of Gene Therapy in Cartilage Repair.The archives of bone and joint surgery · 2019Review
- Combinatorial Prg4 and Il-1ra Gene Therapy Protects Against Hyperalgesia and Cartilage Degeneration in Post-Traumatic Osteoarthritis.Human gene therapy · 2019Article
- Customized biomaterials to augment chondrocyte gene therapy.Acta biomaterialia · 2017Article
- Reduction of friction by recombinant human proteoglycan 4 in IL-1α stimulated bovine cartilage explants.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2017Article
- Inhibition of vascular endothelial growth factor with shRNA in chondrocytes ameliorates osteoarthritis.Journal of molecular medicine (Berlin, Germany) · 2016Article
- Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment.Scientific reports · 2016Article
- Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes.Molecular therapy. Methods & clinical development · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Osteoarthritis (OA) is the Western world's leading cause of disability. It is incurable, costly and responds poorly to treatment. This review discusses strategies for treating OA by gene therapy. As OA affects a limited number of weight-bearing joints and has no major extra-articular manifestations, it is well suited to local, intra-articular gene therapy. Possible intra-articular sites of gene transfer include the synovium and the cartilage. Most experimental progress has been made with gene transfer to synovium, a tissue amenable to genetic modification by a variety of vectors, using both in vivo and ex vivo protocols. The focus so far has been upon the transfer of genes whose products enhance synthesis of the cartilaginous matrix, or inhibit its breakdown, although there is certainly room for alternative targets. It is possible to build a convincing case implicating interleukin-1 (IL-1) as a key mediator of cartilage loss in OA, and the therapeutic effects of IL-1 receptor anatagonist (IL-1Ra) gene transfer have been confirmed in three different experimental models of OA. As transfer of IL-1Ra cDNA to human arthritic joints has already been accomplished safely, we argue that clinical studies of intra-articular IL-1Ra gene transfer in OA are indicated and should be funded. Of the available vector systems, recombinant adeno-associated virus may provide the best combination of safety with in vivo delivery using current technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.